InVivo Therapeutics Adds Senior Leadership in Manufacturing and Cell Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), announced today the appointment of Jack Harvey as Senior Director of Manufacturing and Celina Chang as Senior Scientist as the Company ramps up preparations for a human clinical trial and begins to expand its product portfolio to other nervous system conditions.

Mr. Harvey will lead InVivo Therapeutics production of GMP polymer-based biomaterial technologies. Leveraging his seven years as the Director of Manufacturing at Pervasis Therapeutics, Inc., where he led combination biomaterial and cell therapy products through the FDA, Mr. Harvey will lend his knowledge to InVivos existing and future product pipeline. He will manage contracted and internal resources as well as Chemistry, Manufacturing and Control (CMC) development and manufacturing scale up. Mr. Harvey received his B.A. in biology from Harvard University and his M.P.H. Health Law from Boston University, School of Public Health.

Im excited to lead InVivos optimization of GMP biomaterial technology manufacturing processes, Mr. Harvey said. Spinal cord injury treatments are a very promising field, and Im eager to provide patients with viable solutions for SCI and other nervous system disorders.

Ms. Chang also previously worked at Pervasis as a scientist charged with process improvement for the companys three-dimensional polymer matrix embedded with cells. At InVivo Therapeutics, Ms. Chang will lead the execution and review of experiments per GMP and GLP regulations, and undertake the analysis of various cultured cells for InVivos chronic spinal cord injury therapies. Prior to Pervasis, Ms. Chang worked at Ortec International, focused on advancing regenerative medicine and stem cell therapies. She holds a B.S. in biological engineering from Cornell University.

We strongly believe that combination therapies are the future of chronic spinal cord injury, and I look forward to developing these technologies, said Ms. Chang.

Said InVivo Chief Executive Officer Frank Reynolds, InVivo is at an inflection point in our growth, and adding industry leaders like Jack and Celina will take our platform technology in new directions. We are creating a new paradigm in the treatment of neurological injuries, and as our team evolves we are pleased that we continue to attract the best in our business, enabling us to expedite our products to market.

For more information about InVivo Therapeutics technologies, visit http://www.invivotherapeutics.com.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, Mass. For more details, visit http://www.invivotherapeutics.com.

Link:
InVivo Therapeutics Adds Senior Leadership in Manufacturing and Cell Research